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Background
Bortezomib targets molecular dysregulation of nuclear factor-κB activation and cell cycle 
control, which are characteristic features of diffuse large B-cell lymphoma (DLBCL). We 
evaluated the safety and efficacy of bortezomib treatment with dose-dense cyclo-
phosphamide, doxorubicin, vincristine, and prednisone (CHOP) every 2 weeks 
(CHOP-14).
Methods
Untreated DLBCL patients were enrolled. A phase I dose-escalation study with 1.0, 1.3, 
and 1.6 mg/m
2 bortezomib administration on day 1 and 4 in addition to the CHOP-14 
regimen was performed to determine the maximum tolerated dose (MTD) and the 
dose-limiting toxicity (DLT). Lenograstim 5 μg/kg/d was administered on day 4-13. The 
bortezomib dose from the phase I study was used in the phase II study.
Results
Nine and 37 patients were enrolled in the phase I and phase II studies, respectively. The 
analysis of the phase II results (40 patients) included data of the 3 patients in the last MTD 
dose cohort of the phase I trial. During the phase I trial, no DLT was observed at any borte-
zomib dose; therefore, the recommended dose was 1.6 mg/m
2. In phase II, the overall 
response rate was 95% (complete response: 80%; partial response: 15%). Nine out of 
the 40 patients showed grade 3 sensory neuropathy, and 22 required at least 1 dose 
reduction. Three patients could not complete the intended 6 cycles of treatment because 
of severe neuropathy.
Conclusion
Bortezomib plus CHOP-14 was highly effective for the treatment of untreated DLBCL pa-
tients, but in many cases, dose or schedule modification was required to reduce 
neurotoxicity.
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INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is an aggressive 
B-cell disorder and the most common lymphoma subtype 
in adults [1]. Patients without risk factors generally have 
a favorable prognosis, whereas patients with a resistant or 
recurrent form of the disease often have unfavorable out-
comes. Although the addition of rituximab (R) to the chemo-
therapy regimen of cyclophosphamide, doxorubicin, vincris-
tine, and prednisone (CHOP) has improved outcomes for 
patients with advanced-stage DLBCL [2-4], treatment resist-
ance is a common problem; thus, more effective strategies 
are necessary to further improve patient outcomes [1]. 
Moreover, dose intensification of CHOP by shortening the 
interval between cycles to 14 days (CHOP-14) also improved Korean J Hematol 2012;47:53-9.
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survival rates, but these rates remain unsatisfactory [5-9]. 
Therefore, new active drugs and treatment strategies are 
needed to improve outcomes in patients with advanced 
DLBCL.
Bortezomib, a novel small-molecule proteasome inhibitor, 
has demonstrated single-agent activity in patients with man-
tle cell lymphoma [10, 11]. Bortezomib inhibits nuclear fac-
tor-κB (NF-κB) activation and has been shown to induce 
apoptosis and sensitize tumor cells to chemotherapy and 
radiation [12]. Gene expression profiling studies of DLBCL 
have identified overexpression of NF-κB as a potential ther-
apeutic target in the activated B-cell (ABC) subtype of 
DLBCL; patients with this subtype have shown poorer out-
comes in response to conventional chemotherapy than those 
with the germinal center B cell (GCB) subtype of DLBCL 
[13, 14]. Although bortezomib has minimal efficacy as a 
single agent in patients with refractory and recurrent DLBCL, 
its combination with dose-adjusted chemotherapy is not asso-
ciated with significant increase in toxicity, suggesting that 
bortezomib may be safely combined with chemotherapy [1, 
13].
We conducted a phase I/II trial of bortezomib in combina-
tion with CHOP-14 in previously untreated patients with 
advanced-stage DLBCL. Because of the potential for over-
lapping toxicities, we initiated the study by performing a 
phase I dose-escalation of bortezomib plus CHOP-14 to de-
termine the maximum tolerated dose (MTD) and dose-limit-
ing toxicity (DLT) of bortezomib. Using the bortezomib dose 
from the phase I trial, we performed a phase II trial to 
test the efficacy and safety of bortezomib plus CHOP-14 
in patients with advanced-stage DLBCL. This study was regis-
tered at www.clinicaltrials.gov as NCT00379574.
MATERIALS AND METHODS
1. Patients
Patients aged ＜70 years with histologically confirmed 
DLBCL and no prior history of any anti-cancer treatment, 
including chemotherapy or radiotherapy, were eligible. All 
patients had the following characteristics: an Eastern Cooper-
ative Oncology Group (ECOG) performance status of 0-2; 
at least 1 unidimensionally measurable lesion; and adequate 
organ functions, defined as absolute neutrophil count (ANC) 
of ≥1,500/mm
3, platelet count of ≥75,000/mm
3, serum crea-
tinine level of ≤2.0 mg/dL, estimated creatinine clearance 
of ≥50 mL/min, bilirubin level of ＜1.25× the upper limit 
of normal (ULN), and serum aminotransferase level ≤2.5 
×ULN. Patients with any of the following characteristics 
were excluded: grade 2 or higher peripheral neuropathy; 
a history of hypersensitivity to bortezomib, boron, or man-
nitol; or a serious medical or psychiatric illness. Women 
who were pregnant or breast-feeding were also excluded 
from the study. The study was approved by the ethics com-
mittee of each participating institution, and all patients were 
provided written informed consent. The study was performed 
in accordance with the Declaration of Helsinki and Good 
Clinical Practice guidelines.
2. Study design and treatment
This study had a non-comparative phase I/II design. In 
phase I, we identified the MTD of bortezomib when it was 
combined with the CHOP-14 regimen, which was the recom-
mended dose for phase II. In phase II, we evaluated the 
efficacy and safety of the bortezomib plus CHOP-14 regimen.
CHOP-14 treatment consisted of cyclophosphamide 750 
mg/m
2 on day 1, doxorubicin 50 mg/m
2 on day 1, vincristine 
1.4 mg/m
2 (up to 2 mg/m
2) on day 1, and prednisolone 100 
mg/d on day 1 through 5 every 14 days. The maximum 
number of cycles was 6, unless patients showed progressive 
disease or unacceptable toxicity, or withdrew consent. 
Patients also received 5 μg/kg/d lenograstim (Neutrogin
Ⓡ, 
JW Pharmaceutical Corp., Seoul, Korea) subcutaneously on 
day 4-13. Bortezomib was administered on day 1 and 4. 
In phase I, bortezomib was administered at doses of 1.0, 
1.3, and 1.6 mg/m
2 to consecutive cohorts with 3 patients 
each; dose escalation over 1.6 mg/m
2 was not planned accord-
ing to a previous phase I study of bortezomib and CHOP-21 
[15, 16]. DLTs were defined as grade 4 neutropenia associated 
with fever for more than 3 days; grade 4 neutropenia lasting 
for more than 10 days; grade 3-4 thrombocytopenia with 
grade 2 hemorrhage; or grade 3-4 non-hematologic toxicity 
during the first treatment cycle.
Three patients were enrolled at each dose level, and dose 
e s c a l a t i o n  c o n t i n u e d ,  i f  n o  D L T  w a s  o b s e r v e d  i n  a n y  o f  
the patients; however, intra-patient dose escalation was not 
allowed. When DLT was observed in a single patient, 3 
additional patients were treated with the same dose. When 
2 or more of 6 patients developed DLT, the previous dose 
level was considered as the MTD. When only 1 of 6 patients 
developed DLT, dose escalation continued.
Patients with an ANC of ≥1,500/mm
3, platelet count of 
≥75,000/mm
3, and non-hematologic toxicity of ≤grade 1 
were administered the same treatment as that in the previous 
treatment cycle. Doses of cyclophosphamide and doxorubicin 
were reduced by 25%, if ANC and platelet recovery exceeded 
1 week; the doses were reduced by 50%, if the delay was 
more than 2 weeks. When a 3-week delay was required 
to recover from bortezomib-related toxicity, bortezomib dose 
was reduced by 1 dose level (e.g., from 1.6 to 1.3 mg/m
2) 
in the subsequent cycles. If the next cycle was also delayed 
for more than 3 weeks because of toxicity, the subject was 
withdrawn from the study.
During phase II, we evaluated the complete response (CR) 
rate, event-free survival (EFS), overall survival (OS), and 
safety of the bortezomib plus CHOP-14 regimen.
3. Evaluation
Toxicity was evaluated every week by history taking, phys-
ical examination, complete blood counts, biochemical tests, 
and other appropriate studies. Toxicities were graded accord-
ing to the Common Terminology Criteria for Adverse Events 
(CTCAE) version 3. Treatment response was evaluated after 
3 cycles and 6 cycles by using the International Working Korean J Hematol 2012;47:53-9.
Bortezomib and CHOP-14 phase I/II study 55
Table 1. Baseline characteristics of the patients (N=49).
Age
    Median (Range), yr 54 (27-70)
Gender
    Male 25 (51.5%)
    Female 24 (48.5%)
Ann Arbor stage
    II   4 (8.2%)
    III 10 (20.4%)
    IV 26 (71.4%)
B symptom
    Yes 22 (44.9%)
    No 27 (55.1%)
ECOG performance status
    0 10 (20.4%)
    1 18 (36.7%)
    2 21 (42.9%)
Extranodal involvement
    0-1 31 (63.3%)
    ＞1 18 (36.7%)
Bone marrow involvement
    Yes   4 (8.2%)
    No 45 (91.8%)
Age-adjusted IPI
    Low risk   6 (12.2%)
    Low intermediate risk 23 (46.9%)
    High intermediate risk 13 (26.5%)
    High risk   7 (14.4%)
Abbreviations: IPI, international prognostic index; ECOG, Eastern 
Cooperative Oncology Group.
Fig. 1. Profile of the phase I and 
phase II trials.
Group response criteria [17]. After the end-of-study visit, 
patients were followed every 4-12 weeks for a minimum 
of 2 years after enrollment and if possible for 5 years.
All time-to-event variables were estimated using the 
Kaplan-Meier method. EFS was defined as the interval be-
tween the date of start of treatment and the date of docu-
mented disease progression or death from any cause, which-
ever happened first. OS was defined as the interval between 
the date of start of treatment and date of death from any 
cause.
RESULTS
1. Patients
Nine patients were enrolled between December 2006 and 
April 2007 for the phase I study, and 37 patients were sub-
sequently enrolled until November 2009 for the phase II 
study. The phase II study included 40 patients, including 
3 patients from cohort 3 of the phase I study (Fig. 1). Patient 
characteristics are summarized in Table 1. The median pa-
tient age was 54 years (range, 27-70 years), and most patients 
(71.4%) had stage IV disease.
2. Phase I determination of bortezomib dose
No DLT was seen at the 3 dose levels of bortezomib (1.0, 
1.3, and 1.6 mg/m
2) during the first cycle. Therefore, the 
recommended dose of bortezomib for phase II was de-
termined to be 1.6 mg/m
2 when combined with CHOP-14. 
A patient in cohort 1 (dose, 1.0 mg/m
2 bortezomib) refused 
to receive bortezomib on d 4 of cycle 6 because of grade 
2 neuropathic pain; this patient was not replaced. In cohort 
2 (dose, 1.3 mg/m
2), a patient showed disease progression 
after 5 cycles and received salvage chemotherapy. In cohort 
3 (dose, 1.6 mg/m
2), 1 patient experienced grade 3 abdominal 
pain with nausea and vomiting, followed by paralytic ileus 
after the second cycle. Because these symptoms were de-
termined to be associated with treatment-related neuro-
pathy, which did not resolve to grade 1 within 3 weeks, 
the patient was dropped from the study. This patient, how-
ever, was treated with CHOP-14, without bortezomib, during 
cycles 3-6. There were no other dose reductions or delays.
3. Disposition of patients and treatment delivery
The most common reason for withdrawal from either 
phase was adverse events. In the phase I study, 1 of the 
3 patients in cohort 1 failed to complete the 6 cycles of 
treatment because of neuropathic pain, and 1 patient of 3 
in cohort 3 failed to complete treatment because of paralytic 
ileus accompanied by neuropathy (Fig. 1). One patient in 
cohort 2 showed progressive disease before completion of 
the 6 cycles of therapy and stopped treatment.
In phase II, 30 patients (75.0%) completed 6 cycles of 
bortezomib plus CHOP-14; 10 patients did not complete 
treatment. Five patients discontinued treatment because of 
severe adverse events, including severe sensory neuropathy, Korean J Hematol 2012;47:53-9.
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Table 2. Adverse events after bortezomib plus CHOP-14 treatment (N=49).
Grade
Phase I (N=9) Phase II (N=40)
Bortezomib dose (mg/m
2)
1.0 (N=3) 1.3 (N=3) 1.6 (N=3)
All doses
1.6
3 4 3 4 3 4 3 4
Hematologic, N (%)
    Anemia - - - - 1 - 1 (11.1%) 17 (42.5%)   4 (10.0%)
    Thrombocytopenia - - 1 - - 1 2 (22.2%)   5 (12.5%)   6 (15.0%)
    Neutropenia - - - 1 - 1 2 (22.2%) 3 (7.5%)   9 (22.5%)
    Febrile neutropenia - - 1 - - - 1 (11.1%)   6 (15.0%) -
Non-hematologic, N (%)
    Abdominal pain - - - - 1 - 1 (11.1%) 3 (7.5%) -
    A n o r e x i a ------ - - -
    Constipation - - - - - - - - 1 (2.5%)
    Diarrhea - - - - - - -   4 (10.0%) 1 (2.5%)
    Fever - - - - - - -   4 (10.0%) -
    F a t i g u e ------ - 2  ( 5 . 0 % ) -
    N a u s e a ----1- 1  ( 1 1 . 1 % ) - -
    V o m i t i n g ----1- 1  ( 1 1 . 1 % ) 1  ( 2 . 5 % ) -
    Hyperglycemia - - - - - - -   4 (10.0%) -
    Hypoalbuminemia - - - - - - -   5 (12.5%) -
    Hypocalcemia - - - - - - -   4 (10.0%) 1 (2.5%)
    H y p o k a l e m i a ------ - 3  ( 7 . 5 % ) -
    Sensory neuropathy - - 1 - 1 - 2 (22.2%)   9 (22.5%) -
    Motor neuropathy - - - - - - - 3 (7.5%) -
Table 3. Response after bortezomib plus CHOP-14 treatment.
Phase I Phase II
Bortezomib dose (mg/m
2)
1.0 (N=3) 1.3 (N=3) 1.6 (N=40)
After 3 cycles
    CR 2 2 25 (62.5%)
    PR  1 1 13 (32.5%)
    SD 0 0   0 (0.0%)
    PD 0 0   0 (0.0%)
    Not available 0 0   2 (5.0%)
After completion of treatment
    CR 3 2 32 (80.0%)
    PR  0 0   6 (15.0%)
    SD 0 0   0 (0.0%)
    PD 0 1   0 (0.0%)
    Not available 0 0   2 (5.0%)
Abbreviations: CR, complete response; PR, partial response; SD, 
stable disease; PD, progressive disease.
severe infection, small bowel perforation, pneumonitis with 
bilateral pulmonary infiltration, and uncontrolled delirium; 
each of these events was observed in 1 patient. Two patients 
refused to continue treatment; 2 died of severe pneumonia 
with septic shock during treatment; and 1 showed poor toler-
ance to treatment followed by rapid disease progression. 
Overall, 40 patients received 214 cycles of bortezomib plus 
CHOP-14. The median number of cycles administered per 
patient was 6. The mean percentages of the planned doses 
(i.e., the actual dose divided by the planned full dose) of 
bortezomib, cyclophosphamide, vincristine, and doxorubicin 
were 90.6%, 99.2%, 98.6%, and 99.2%, respectively.
4. Toxicity
Grade 3 or 4 adverse events during phases I and II are 
summarized in Table 2. During both phases, myelosup-
pression was rare. Among non-hematologic toxicities, sen-
sory neuropathy was the most common adverse event, occur-
ring in 22.2% of patients in both phases I and II; 9 patients 
showed grade 3 sensory neuropathy (3 patients after 3 cycles 
of treatment and 6 patients after 4 cycles of treatment). 
Three patients showed grade 3 motor neuropathy. Grade 
1 and 2 neuropathy was also common, occurring in 17.5% 
(grade 1) and 30.0% (grade 2) of patients, respectively.
Of the 40 patients in the phase II trial, 22 (55.0%) required 
bortezomib dose reduction from 1.6 mg/m
2 to 1.3 mg/m
2 
because of toxicities. The most common toxicity was grade 
≥3 neuropathy, which occurred after median 4 cycles of 
treatment. Three patients required 2 dose reductions of borte-
zomib from 1.6 mg/m
2 to 1.0 mg/m
2 because of neuropathy.
5. Response
Two patients in cohort 1 of phase I achieved CR, 1 patient 
achieved PR after 3 cycles of treatment. In cohort 2 of phase 
I, all 3 achieved CR after completion of treatment and 2 
patients achieved CR and 1 achieved PR after 3 cycles of 
treatment; however, 1 patient showed tumor progression 
after completion of treatment (Table 3).
In phase II, 25 patients achieved CR and 13 patients ach-
ieved PR after 3 cycles of treatment. After completion of Korean J Hematol 2012;47:53-9.
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Fig. 2. (A) Event-free survival (EFS) and (B) overall survival (OS) of patients in the phase II study.
treatment, 32 patients achieved CR and 6 patients achieved 
PR, with an overall response rate (ORR) of 95%. At median 
follow-up of 16.1 months, 10 patients showed disease pro-
gression or relapse and 8 died. The overall 2-year EFS rate 
was 60.6% and the 2-year OS rate was 75.1% (Fig. 2).
DISCUSSION
We evaluated the safety and efficacy of the bortezomib 
plus dose-dense CHOP-14 regimen in patients with ad-
vanced-stage DLBCL. Although no DLT was observed during 
the first cycle of the phase I study and the MTD was not 
reached, we utilized a bortezomib dose of 1.6 mg/m
2 in 
the phase II trial; this dosage showed low toxicity in prior 
phase I/II trials [15, 16, 18].
Our phase II trial showed that treatment with 1.6 mg/m
2 
bortezomib in addition to the CHOP-14 regimen on day 
1 and 4 resulted in an overall response rate of 95%, including 
CR rate of 80% and PR rate of 15%. However, 9 of the 
40 patients (22.5%) experienced grade 3 sensory neuropathy; 
22 patients (55.0%) required at least 1 bortezomib dose reduc-
tion after 4 cycles of treatment, despite close monitoring 
and assessment of neuropathy using functional assessment 
of cancer therapy-neurotoxicity (FACT-NTX). In addition, 
3 patients could not complete the 6 scheduled cycles of 
bortezomib plus CHOP-14 due to severe neuropathy.
Neurotoxicity is a dose-limiting adverse effect of bortezo-
mib, but the mechanism by which bortezomib induces pe-
ripheral neuropathy is still unclear. It is believed to be due, 
at least in part, to damage of mitochondria and the endoplas-
mic reticulum caused by the activation of the mitochon-
drial-based apoptotic pathway [19]. In patients with multiple 
myeloma, the incidence of neuropathy increases with the 
cumulative dose of bortezomib, often reaching a plateau 
after the first 5 cycles in patients treated with single-agent 
bortezomib. Because prolonged proteasome inhibition is like-
ly to result in increased neurotoxicity, determination of the 
DLT after only 1 cycle of treatment in our phase I trial 
may not be suitable for evaluating the neurotoxicity observed 
after 6 cycles.
Several studies using the combination of bortezomib plus 
chemotherapy have been undertaken or are ongoing. The 
overlapping neurotoxicities of vincristine and bortezomib 
have limited the success of these trials. In combination with 
DA-EPOCH, the MTD of bortezomib was 1.7 mg/m
2 (day 
1 and 4) in patients with previously treated DLBC [20]. 
However, the subsequent phase 2 trial used a bortezomib 
dose of 1.5 mg/m
2 because neuropathy resulted in dis-
continuation of bortezomib after the patient had received 
multiple doses of the drug. However, in patients with un-
treated indolent B-cell lymphoma, bortezomib doses of up 
to 1.6 mg/m
2 were added to the R-CHOP regimen on day 
1 and 8, with vincristine capped at a dose of 1.5 mg. At 
these doses, treatment was well tolerated, with only 1 patient 
experiencing grade 3 neuropathy [21]. A recent randomized 
phase 2 study comparing 2 schedules of bortezomib plus 
R-CHOP also showed that neurological toxicity was more 
frequent and severe when bortezomib was administered bi-
weekly (days 1, 4, 8, and 11) rather than weekly (days 1 
and 8) [22]. Another phase 2 study, which used 1.3 mg/m
2 
bortezomib with standard doses of R-CVP (BR-CVP; bortezo-
mib, rituximab, cyclophosphpamide, vincristine, and pre-
dnisolone) in patients with advanced-stage follicular lym-
phoma, found that no patient developed grade 4 neuro-
toxicity and only 5% developed grade 3 neurotoxicity [23]. 
Therefore, neurotoxicity in patients treated with bortezomib 
plus CHOP-14 may be reduced by modifying the bortezomib 
dose or schedule (days 1 and 8 rather than days 1 and 4), 
or by reducing or eliminating the dose of vincristine in 
the CHOP-14 regimen.
The overall response rate after treatment with bortezomib 
plus CHOP-14 was 95%, with 80% of patients achieving 
CR. These response rates were higher than those observed 
with R-CHOP-14 (ORR: 77%, including 43% CR, 20% CR, 
and 14% PR) and even R-CHOEP (cyclophosphamide, doxor-Korean J Hematol 2012;47:53-9.
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ubicin, vincristine, etoposide, and prednisolone) -14 (ORR: 
91%, including 53% CR, 25% CRu, and 13% PR). Because 
62.5% of our patients achieved CR after just 3 cycles of 
treatment, the combination of bortezomib with CHOP-14 
may induce an early treatment response.
The activity of the NF-κB signaling pathway is a dis-
tinguishing feature of the ABC subtype of DLBCL, which 
has a poorer prognosis than the GCB subtype when treated 
with doxorubicin-containing chemotherapy [21, 22, 24]. 
Bortezomib enhanced the activity of chemotherapy in cases 
involving the ABC, but not the GCB subtype of DLBCL, 
providing a rational therapeutic approach based on genet-
ically distinct DLBCL subtypes [1]. We could not analyze 
differences in efficacy on the basis of the DLBCL subtypes 
due to a lack of information on gene expression profiling 
and immunohistochemical analysis of tumors. Furthermore, 
although we found that bortezomib plus CHOP yielded a 
high response rate in DLBCL patients, we did not compare 
this regimen with R-CHOP, which is the current standard 
of care for DLBCL; therefore, further investigations of the 
efficacy of our regimen are necessary prior to its acceptance 
as another treatment option.
The major limitation of this study was that none of our 
DLBCL patients was treated with rituximab. Trials of bortezo-
mib plus R-CHOP were in progress when we planned this 
trial. The Korean Food and Drug Administration recently 
approved the use of rituximab with CHOP every 3 weeks 
in patients with DLBCL. This study was initiated before 
the publication of the MInT [4] and RICOVER-60 trials 
[25]. These administrative issues and limited research funds 
were responsible for the absence of rituximab in our treat-
ment protocol.
In conclusion, we found that the combination of bortezo-
mib with CHOP-14 showed a high response rate in untreated 
DLBCL patients. However, modification of the dose or sched-
ule of bortezomib is needed to reduce neurotoxicity.
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